...
首页> 外文期刊>Apoptosis: An international journal on programmed cell death >Blockade of PKCβ protects against remote organ injury induced by intestinal ischemia and reperfusion via a p66shc-mediated mitochondrial apoptotic pathway
【24h】

Blockade of PKCβ protects against remote organ injury induced by intestinal ischemia and reperfusion via a p66shc-mediated mitochondrial apoptotic pathway

机译:PKCβ的阻断通过p66shc介导的线粒体凋亡途径防止肠道缺血和再灌注引起的远端器官损伤

获取原文
获取原文并翻译 | 示例
           

摘要

Intestinal ischemia-reperfusion (I/R) is a serious clinical dilemma with high morbidity and mortality. Remote organ damage, especially acute lung injury and liver injury are common complications that contribute to the high mortality rate. We previously demonstrated that activation of PKCβII is specifically involved in the primary injury of intestinal I/R. Considering the tissue-specific features of PKC activation, we hypothesized that some kind of PKC isoform may play important roles in the progression of secondary injury in the remote organ. Mice were studied in in vivo model of intestinal I/R. The activation of PKC isoforms were screened in the lung and liver. Interestingly, we found that PKCβII was also activated exclusively in the lung and liver after intestinal I/R. PKCβII suppression by a specific inhibitor, LY333531, significantly attenuated I/R-induced histologic damage, inflammatory cell infiltration, oxidative stress, and apoptosis in these organs, and also alleviated systemic inflammation. In addition, LY333531 markedly restrained p66shc activation, mitochondrial translocation, and binding to cytochrome-c. These resulted in the decrease of cytochrome-c release and caspase-3 cleavage, and an increase in glutathione and glutathione peroxidase. These data indicated that activated PKC isoform in the remote organ, specifically PKCβII, is the same as that in the intestine after intestinal I/R. PKCβII suppression protects against remote organ injury, which may be partially attributed to the p66shc-cytochrome-c axis. Combined with our previous study, the development of a specific inhibitor for prophylaxis against intestinal I/R is promising, to prevent multiple organ injury.
机译:肠缺血再灌注(I / R)是严重的临床难题,发病率和死亡率很高。远端器官损伤,特别是急性肺损伤和肝损伤是导致高死亡率的常见并发症。我们先前证明了PKCβII的激活与肠道I / R的原发性损伤特别相关。考虑到PKC激活的组织特异性特征,我们假设某种PKC亚型可能在远端器官继发性损伤的进展中起重要作用。在肠道I / R的体内模型中研究了小鼠。在肺和肝中筛选了PKC同工型的活化。有趣的是,我们发现肠I / R后PKCβII也仅在肺和肝中被激活。通过特异性抑制剂LY333531抑制PKCβII,可显着减轻I / R诱导的组织学损伤,炎性细胞浸润,氧化应激和这些器官的细胞凋亡,并减轻全身性炎症。此外,LY333531显着抑制p66shc激活,线粒体易位以及与细胞色素c的结合。这些导致细胞色素c释放和胱天蛋白酶3切割的减少,以及谷胱甘肽和谷胱甘肽过氧化物酶的增加。这些数据表明,在远端I / R后,远端器官中的活化PKC同工型,特别是PKCβII,与肠道中的相同。 PKCβII抑制可防止远端器官损伤,这可能部分归因于p66shc-cytochrome-c轴。结合我们之前的研究,开发预防肠道I / R的特异性抑制剂有望防止多器官损伤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号